Trial Search Results
Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer
By using stereotactic body radiation therapy (SBRT) delivered with the Cyberknife system®, the current protocol attempts to mimic or improve the excellent local control rates seen in treatment of early stage breast cancer while attempting to increase convenience, limit invasiveness, decrease toxicity, and improve cosmesis compared to other methods of radiation treatment.
Stanford is currently not accepting patients for this trial.
University of Texas Southwestern Medical Center
- Radiation: Stereotactic Body Radiation Therapy
- DCIS or invasive ductal, medullary, papillary, mucinous (colloid), or tubular
- Eligible patients must have appropriate staging studies identifying them as AJCC stage
T1 or T2 (≤3 cm) treated with lumpectomy and axillary node dissection with at least 6
nodes sampled or sentinel node biopsy. Patients with up to 3 positive nodes without
microscopic or macroscopic evidence of extracapsular extension are eligible.
- The patient's Zubrod performance status must be 0-2.
- Patients must be ≥ 18 years of age.
- If chemotherapy is planned, it must begin no earlier than two weeks following
completion of radiation therapy.
- Unifocal breast cancer (no evidence of gross multifocal disease, multicentric, or
- Negative margins after lumpectomy (re-excision for initial positive margins is
allowed-negative margins defined as >2 mm clear of tumor in all directions).
- Negative post- lumpectomy mammography if malignancy-associated microcalcifications
were initially present.
- The target lumpectomy cavity must be clearly delineated.
- Patients must complete appropriate pretreatment evaluation, including post-lumpectomy
mammogram if microcalcifications were initially present to confirm complete removal.
- Evidence of suspicious microcalcifications in the breast prior to start of radiation.
- Patients with history of collagen vascular disease, specifically dermatomyositis with
a CPK level above normal or active skin rash, systemic lupus erythematosis, or
- Patients with 4 or more histologically positive axillary nodes if axillary dissection
- Patients with distant metastases.
- Patients with invasive or extensive in-situ lobular carcinoma or non-epithelial breast
malignancies such as sarcoma or lymphoma.
- Patients with multicentric gross disease defined as tumors in different quadrants of
the breast or tumor separated by at least 4 cm or other clinically or radiographically
suspicious areas in the ipsilateral breast unless confirmed to be negative for
malignancy or biopsy.
- Patients must not have any palpable or radiographically suspicious ipsilateral or
contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes
unless there is histologic confirmation that these nodes are negative for tumor.
- Any previously treated contralateral invasive breast carcinoma or synchronous
contralateral breast carcinoma.
- Prior non-hormonal therapy or radiation therapy for the current breast cancer or
hormonal therapy for > 28 days after diagnosis or refusal to discontinue hormonal
- Patients with Paget's disease of the nipple
- Patients with prior invasive malignancy (except non-melanomatous skin cancer) unless
disease free for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral
cavity, or cervix are all permissible).
- Patients with severe, active co-morbidity.
- Patients with psychiatric or addictive disorders that, in the opinion of the
investigator, would preclude obtaining informed consent.
- Patients who are pregnant or lactating.
- Previous breast radiation on either side or thoracic radiation on the ipsilateral
Ages Eligible for Study
18 Years - 99 Years
Genders Eligible for Study